Blog

AVITA Medical has appointed Cary Vance as Interim CEO following the sudden departure of Jim Corbett, along with a Board reshuffle. The company also announced preliminary third-quarter revenue guidance of about $17 million and is renegotiating financial covenants with OrbiMed.

See our latest analysis for AVITA Medical.

AVITA Medical’s share price has experienced a steep drop, with a 1-day return of -25.84% that extends a longer downtrend; its share price return is now down 68.8% year-to-date and the total shareholder return over the past year is -62.46%. Although new leadership and ongoing financial negotiations have triggered heightened volatility, these developments highlight how shifts in management and guidance can dramatically alter risk perceptions and momentum. Longer-term returns also remain deeply negative.

If recent leadership changes have you rethinking your portfolio, it’s worth broadening your search and discovering fast growing stocks with high insider ownership.

With the share price at multiyear lows and uncertainty clouding the outlook, investors now face a pivotal question: is AVITA Medical undervalued after recent events, or does the current price already reflect limited growth prospects?

Market watchers are comparing AVITA Medical’s last close of $3.99 to a narrative fair value estimate of $8.26 per share, highlighting a sharp disconnect between recent price action and what analysts believe the company is worth. The narrative points to several potential catalysts that could change the trajectory for AVITA and shift sentiment.

“Launch and rapid initial uptake of Cohealyx and PermeaDerm, supported by their integration with RECELL in a comprehensive wound care portfolio, positions AVITA to capture new indications and patient segments beyond burns (e.g., trauma), increasing the company’s total addressable market and diversifying future revenue streams.”

Read the complete narrative.

Want to know what bold growth assumptions power this deeply discounted fair value? Find out which future milestones and transformative launches could unlock the upside. The secret behind this projection is a set of aggressive profit margin and sales targets. What exactly are they?

Result: Fair Value of $8.26 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, persistent Medicare reimbursement delays and continued reliance on RECELL for growth could significantly undermine the bullish narrative and extend uncertainty for investors.

Find out about the key risks to this AVITA Medical narrative.

If you have different insights or want to analyze the numbers for yourself, you can craft your own narrative in just a few minutes. Do it your way.

A great starting point for your AVITA Medical research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.

Don’t limit your opportunities to just one company, when there are so many innovative stocks making headlines right now. Check out these unique investment angles before markets move on:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include RCEL.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Ingrid de Swart has been nominated to succeed Jos Baeten as CEO and Chair of the Executive Board (EB) of ASR Nederland N.V. (a.s.r.) following the end of his term at the Annual General Meeting (AGM) on 20 May 2026.

Joop Wijn, Chair of the SB of a.s.r., stated : “The Supervisory Board is delighted to nominate Ingrid de Swart as Chair of the Executive Board of a.s.r. Ingrid brings a unifying presence, the experience necessary to ensure continuity in a.s.r.’s strategy, and a forward-looking vision to drive the company’s sustainable growth.

“Although Jos Baeten’s departure will take place at a later date, we would already like to express our profound appreciation for everything he has contributed to a.s.r. over more than 45 years. His dedication and leadership have been invaluable. Under his guidance, a.s.r. successfully navigated the financial crisis, completed a successful IPO, achieved growth both organically and through acquisitions, and became one of the leading insurers in the Netherlands.”

Ingrid de Swart is a seasoned veteran of the financial services industry with over 28 years of experience. She has been a member of a.s.r’s EB since December 1, 2019, serving as COO/CTO, and playing a key role in the company’s strategic direction.

In addition, de Swart has been leading the integration of Aegon Nederland into a.s.r. since October 2022. Prior to joining a.s.r., she served as Chair of the Retail Division on the Statutory Board of Aegon Nederland. Her career also includes leadership roles at Delta Lloyd, and ABN AMRO Verzekeringen.

Jos Baeten, CEO of a.s.r., said: “I have had the privilege of leading a.s.r. for more than 20 years. To this day, I continue to do so with great energy and pleasure, and I will carry on until the AGM. I am very proud of what we have achieved with a.s.r.

“We have a strong team, a strategy focused on growth and a robust balance sheet making a.s.r. a company ready for the future. For me personally, the time has come to hand over the leadership. That is why I have informed the Supervisory Board that I am not available for a new term. I am pleased and proud that Ingrid is my intended successor.”

According to the announcement, Baeten who began his career at the company in 1980, will remain involved until his retirement on 1 December 2026.

The intended appointment of Ingrid de Swart is subject to approval by the regulators and  vote at the upcoming AGM.

The a.s.r. Works Council has issued a positive recommendation, and the SB intends to proceed with the appointment for a period of four years.

a.s.r plans to address the EB vacancy arising from de Swart’s intended appointment at a later date/